Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind it.
The agreement – which still needs court approval before it can be finalised – has been made in response to a class action brought by direct purchaser plaintiffs against the company’s US subsidiaries Sandoz Inc and Fougera Pharma.
